T) has faced challenges in 2023, with its stock underperforming the S&P 500. There are indications that the company’s fortunes could turn around in 2024. \n\nFirstly, AT&T has been steadily gaining subscribers in its core wireless business, despite the challenges posed by the pandemic. In the third quarter of 2023, the company reported 468,000 postpaid phone net adds, surpassing rival Verizon’s gain of just 100,000 net postpaid phone subscribers. Additionally, AT&T’s churn rate for postpaid phones remained low at 0.79%, compared to Verizon’s 0.9%.\n\nMoreover, AT&T’s fiber internet business is a long-term growth opportunity for the company. The company’s fiber network has passed 20.7 million locations, with a penetration rate of 39%. \n\nSecondly, AT&T’s free cash flow is expected to increase in 2024, with the company projecting $16.5 billion. This is enough to cover its dividend and also pay down its debt. In fact, the company aims to reduce its net debt to adjusted EBITDA ratio to the 2.5 range by the end of 2023.\n\nEconomic uncertainty and inflation in 2023, AT&T has managed to keep winning customers, which bodes well for its future performance.”

Iovance Biotherapeutics Rebounds After Clinical Hold on IOV-LUN-202 Trial\n\nIovance Biotherapeutics (NASDAQ:IOVA) saw a dramatic 18.7% increase in stock price on Thursday, following a 20% drop the day before. This volatility was caused by a clinical hold placed on the company's IOV-LUN-202 clinical trial by the US Food and Drug Administration (FDA). The trial was evaluating Iovance's LN-145 TIL experimental therapy for non-small-cell lung cancer (NSCLC). The FDA's decision was prompted by a patient's death, which was potentially related to the trial's pre-conditioning regimen.\n\nThis setback, Iovance emphasized the urgent need for treatments in cases like these, where patients have limited options and a poor prognosis. The company has paused enrollment of new patients in the trial and will continue to monitor and follow patients who have already received treatment according to the protocol. Additionally, patients who have undergone tumor resection will continue to receive the LN-145 TIL treatment with additional precautions and risk mitigations.\n\nIt is worth noting that LN-145 TIL is not Iovance's lead drug candidate, and the potential approval of its lifileucel advanced melanoma treatment could generate significant revenue for the company. The recent volatility, opportunistic shareholders are taking advantage of the drop in stock price to invest in Iovance.\n\nThe Motley Fool Stock Advisor service has a proven track record of success, providing investors with a blueprint for building a successful portfolio and regular updates from analysts. While the clinical hold may delay the completion of the study, Iovance Biotherapeutics has the potential to generate significant revenue with its lifileucel treatment.